Evaluation of Bach1 mRNA expression in patients with chronic kidney disease: A preliminary study

Abstract

AbstractIntroductionBTB and CNC homology 1 (Bach1) is a protein that antagonizes some actions of nuclear factor erythroid 2‐related factor‐2 (Nrf2), the master regulator of cytoprotective responses. Bach1 binds to genomic DNA and inhibits the synthesis of antioxidant enzymes, thereby increasing inflammation. Bach1 may be a therapeutic target for mitigating inflammation in chronic kidney disease (CKD) patients. However, no clinical study has been reported on Bach1 in this population. This study aimed to evaluate Bach1 mRNA expression with different treatments for CKD, including conservative treatment (nondialysis), hemodialysis (HD), and peritoneal dialysis (PD).MethodsTwenty patients undergoing HD (56.5 [19] years), 15 on PD (54 [24] years) and 13 nondialysis patients (63 [10] years, with an estimated glomerular filtration rate of 41 [14] mL/min/1.73 m2) were enrolled in the study. The mRNA expression of Nrf2, NF‐kB, heme oxygenase 1 (HO‐1), and Bach1 was evaluated in peripheral blood mononuclear cells using quantitative real‐time polymerase chain reaction. Malondialdehyde (MDA) was evaluated as a lipid peroxidation marker. Routine biochemical parameters were also evaluated.FindingsAs expected, patients on dialysis were more inflamed. Bach1 mRNA expression was significantly higher in patients undergoing HD than in PD and nondialysis patients (p < 0.007). The mRNA expression of HO‐1, NF‐kB, and Nrf2 was not different in the groups.ConclusionIn conclusion, CKD patients on HD exhibited an upregulation of Bach1 mRNA expression compared to patients on PD treatment and nondialysis CKD patients. The association between Nrf2 and Bach1 expression in these patients warrants further investigation.